Proteasome inhibitory activity of thiazole antibiotics

Cancer Biology and Therapy

Volumn 11, Issue 1, 2011, Pages 43-47

  Pandit, Bulbul ^a   Bhat, Uppoor ^a   Gartel, Andrei L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Apoptosis; FoxM1; Proteasome inhibitors; Thiazole antibiotics; Thiostrepton

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BERNINAMYCIN; BORTEZOMIB; METACYCLINE; MICROCOCCIN P1; MICROCOCCIN P2; PROTEASOME INHIBITOR; THIAZOLE DERIVATIVE; THIOCILLIN; THIOSTREPTON; UNCLASSIFIED DRUG; YM 266183;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; PROTEIN MODIFICATION;

ANTI-BACTERIAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MACROCYCLIC COMPOUNDS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; THIAZOLES;

EID: 78751485542     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.1.13854     Document Type: Article

References (13)

1. Jonker HR, Ilin S, Grimm SK, Wohnert J, Schwalbe H. L11 domain rearrangement upon binding to RNA and thiostrepton studied by NMR spectroscopy. Nucleic Acids Res 2007; 35:441-54.
2. Harms JM, Wilson DN, Schluenzen F, Connell SR, Stachelhaus T, Zaborowska Z, et al. Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol Cell 2008; 30:26-38.
3. Bowers AA, Acker MG, Koglin A, Walsh CT. Manipulation of thiocillin variants by prepeptide gene replacement: structure, conformation and activity of heterocycle substitution mutants. J Am Chem Soc 2010; 132:7519-27.
4. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 2006; 66:9731-5.
5. Bhat UG, Zipfel PA, Tyler DS, Gartel AL. Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle 2008; 7:1851-5.
6. Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS ONE 2009; 4:5592.
7. Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS ONE 2009; 4:6593.
8. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78:761-71.
9. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, et al. Lactacystin and clastolactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997; 272:13437-45.
10. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21:30-6.
11. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004; 18:830-50.
12. Schoof S, Pradel G, Aminake MN, Ellinger B, Baumann S, Potowski M, et al. Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action. Angewandte Chemie International ed 2010; 49:3317-21.
13. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14:451-6.